Novartis explains stance over India patent law challenge

Article Date: 27/02/2012 08:00
Novartis explains stance over India patent law challenge

Vacancy Search

Quick job search

Advanced Search

Latest News

NICE recommends new licences for autoinflammatory disorders

NICE recommends new licences for autoinflammatory disorders

FDA approves Salix and Actavis IBS drugs

FDA approves Salix and Actavis IBS drugs

FTC sees too much Synergy in Steris deal

The last year has seen a number of merger agreements between very similar medtech companies apparently unbothered by antitrust rules and tax laws. Now the US Federal Trade Commission has...

Upcoming events – phase III antibiotic data for Merck and Glaxo asthma panel

Welcome to your weekly digest of approaching regulatory and clinical readouts. Phase III data on one of the antibiotics Merck & Co obtained via its takeover of Cubist is expected mid-year,...

UK government commits to health spend increases

UK government commits to health spend increases

Gilead-backed Hep B vaccine fails

Gilead-backed Hep B vaccine fails

Eight new medicines recommended by CHMP

Eight new medicines recommended by CHMP

Bayer plans corporate restructure

Bayer plans corporate restructure

Event – BioLineRx and Bellerophon hope for a matrix revolution

The cardiac matrix under development by BioLineRx and Bellerophon Therapeutics to limit tissue damage after heart attack has already been shown to be safe and well tolerated. Results due by...

Sanofi’s Jevtana given last-minute CDF reprieve

Sanofi’s Jevtana given last-minute CDF reprieve
more news